EDITORIAL COMMENT

The new Clinical Kidney Journal, 4 years later

Alberto Ortiz1 and Caroline Vinck2

1Editor-in-Chief, Clinical Kidney Journal, IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid; Fundacion Renal Inigo Alvarez de Toledo-IRSI and REDINREN, Madrid, Spain and 2ERA-EDTA Editorial Office Coordinator, Lede, Belgium

Correspondence and offprint requests to: Alberto Ortiz; E-mail: aortiz@fjd.es

ABSTRACT

The February 2015 issue of ckj started a new era with renewed efforts to be useful to the training and practicing nephrologists and a new focus on Clinical and Translational Nephrology. Four years later, it has become a truly global journal with contributors and readers from all over the world. The increase in quality of the published material has resulted in a nearly exponential growth of citations. Since 2016, ckj is listed in the new Emerging Sources Citation Index (ESCI) database from Clarivate Analytics and from January 2019 it will be listed in the full Science Citation Index. ckj will therefore receive its first official impact factor based upon 2018 citation to 2016 and 2017 articles. While no official impact factor was awarded for 2017, the estimated impact factors calculated from data available in Clarivate’s Web of Science database rose to 2.987 in 2017, which would correspond to an estimated journal impact factor percentile of 72.4% in the Urology and Nephrology field.

Keywords: acute kidney injury, chronic kidney disease, epidemiology, onconephrology

NDT Plus was launched in 2008. The Editor-in-Chief, Norbert Lameire, aimed at providing an educational and training resource for practicing nephrologists [1]. In 2012, NDT Plus evolved into the Clinical Kidney Journal (ckj) and flourished as an educational tool under the editorship of Alain Meyrier [2, 3]. In 2015, Alberto Ortiz was elected Editor-in-Chief for a first term that just ended. A sub-heading was added to ckj emphasizing the new focus: Clinical and Translational Nephrology [4]. The vision was further expanded in a series of articles on Translational Nephrology [5, 6]. The journal became open access, online-only, and fully searchable and accessible through PubMed. Submission and publishing fees have been waived ever since. The types of manuscripts were streamlined to editorial comments, ckj reviews, original articles and exceptional case reports.

Over the past 4 years, the number of published items decreased when compared with the younger ckj (Figure 1A). This was a consequence of a higher quality threshold for publication. Thus, the number of submissions was 449 in 2015 and is expected to hover around 480 in 2018. However, the acceptance rate decreased from 40% in 2013 to 36% in 2015 and 26% in 2018. The types of manuscripts published shifted to an increase of high-quality ckj reviews and original manuscripts. These changes were well received by the nephrological community and the number of citations per year exponentially increased (Figure 1B). In 2016, ckj was accepted for indexing in the new Emerging Sources Citation Index (ESCI) database from Clarivate Analytics (previously Thomson Reuters). From January 2019 it will be listed in the full Science Citation Index. ckj will therefore receive its first official impact factor based upon 2018 citation to 2016 and 2017 articles. While no official impact factor was awarded for 2017, the estimated impact factor calculated from data available in Clarivate’s Web of Science database rose to 2.987 in 2017 (Figure 2A). In this regard, it is estimated that ckj is approaching the first quartile (Q1, 25% top journals as assessed by impact factor) in the Urology and Nephrology field (Figure 2B). In the 2017 impact factor database, released in June 2018, ckj was listed in the second quartile (Q2). In the 2018 impact factor database, released in June 2019, ckj is expected to be listed in the first quartile (Q1). The impact factor is a measure of the frequency with which the “average article” in a journal has been cited in a particular year by the articles published in the same journal during the previous two years. The impact factor is calculated as the ratio of citations received in a particular year to the number of articles published in the two previous years. The impact factor is a widely used indicator of the relative importance of a journal within its field. A higher impact factor indicates that articles in the journal are more frequently cited by other researchers. The impact factor is used to rank journals within a specific field and to compare the relative influence of different journals. The impact factor is calculated by dividing the number of citations received in a specific year by the number of articles published in the two previous years. The impact factor is a widely used indicator of the relative importance of a journal within its field and is used to rank journals within a specific field and to compare the relative influence of different journals.
2018, there were 10 Urology and 9 Nephrology journals in Q1. Of the latter, only five published original manuscripts.

*ckj* has become a global reference for practicing nephrologists. The main geographical origin of submissions is the USA (22–25% across 2015–18). On the other side of the coin, the top five user countries were, in this order, USA, Great Britain, India, Canada and Australia. However, there were users from a total of 210 countries in 2018, making it a truly global journal (Figure 3).

The most cited manuscripts in this new era are listed in Tables 1–3. Over the past 4 years, the most cited items were ERA-EDTA Registry reports and systematic reviews (Table 1) [7–18]. As expected, older items have gathered more citations. Thus, we provide one table focusing on 2017 (Table 2) and one for 2018 (Table 3) [19–45]. Among the most cited topics, we find systematic reviews and meta-analysis on exercise, vitamins K and D, and assessment of renal function and injury, including the use of a urine peptidomics-based marker of kidney injury recently refined to beat glomerular filtration rate and urinary albumin:creatinine ratio for prediction of chronic kidney disease (CKD) progression when the estimated glomerular filtration rate is still not diagnostic of CKD [46]. Other topics that drew the attention of authors were onconephrology, the interrelationship of the gut microbiota and kidney disease, low-protein diets, residual renal function, eculizumab, sustainability of renal replacement therapy, socioeconomic and psychosocial factors and gender impact on CKD, CKD hotspots, management of hyperphosphataemia, hyperkalaemia, hyperuricaemia and acute kidney injury (AKI). Many topics were shared with the 100 most cited papers in nephrology, presented in this issue of *ckj*, suggesting overall clinical interest for the nephrological community. Shared topics include renal function assessment, pharmacology, dialysis/transplantation, AKI and CKD [47].

In contrast, the top downloaded articles were very practical in approach and included the 2017 update on pain management in patients with CKD [48] and a manuscript on palliative care for patients with end-stage renal disease [49], both published in 2017. In 2018, the top downloaded articles dealt with high-dose vitamin K for calciphylaxis [50], therapy of childhood C3 glomerulopathy [51] and hyponatraemia in kidney transplant patients [52].

A different vision of the impact of *ckj* is provided by the Altmetrics score. In 2018, the three top manuscripts dealt with the ‘ExTra CKD’ trial of supervised exercise in CKD [53], living kidney donor use of marijuana [54] and the EMPA-KIDNEY study of sodium/glucose cotransporter 2 (SGLT2) inhibitors in CKD [55].

As part of our focus on education, *ckj* has started a collaboration with GlomCon and the ERA-EDTA Young Nephrologists’ Platform in 2018. Up to now, two *ckj* manuscripts have been discussed in the Journal Club webinar with active participation of the Editor-in-Chief and in some cases of the authors [56, 57]. For 2019, the manuscript ‘Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network’ by Sprangers et al. [58] is scheduled to be discussed on 7 May 2019.
Hopefully, we will relay to the next Editor-in-Chief, to be elected in 2021, an internationally renowned journal that continues to be a required and useful read for nephrologists-in-training and practicing nephrologists.

FUNDING

Alberto Ortiz was funded by Red Nacional de Investigación en Enfermedades renales (RETIC REDINREN) RD16/0009, Instituto de Salud Carlos III (ISICIII), Government of Spain.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Lameire N, Floege J, Wheeler DC Note from the Editorial Office. NDT Plus 2008; 1: 1
2. Meyrier A, Lameire N. NDT plus introduces the Clinical Kidney Journal. NDT Plus 2011; 4: 367
3. Meyrier A. Report from the Editorial Office. Clin Kidney J 2012; 5: 1–3
4. Ortiz A. Welcome to the new ckj: an open-access resource integrating clinical, translational and educational research into clinical practice. Clin Kidney J 2015; 8: 1–2
5. Ortiz A. Translational nephrology: what translational research is and a bird’s-eye view on translational research in nephrology. Clin Kidney J 2015; 8: 14–22

Table 1. Overall most cited items published in 2015–18

| Rank | Title                                                                 | References |
|------|-----------------------------------------------------------------------|------------|
| 1    | Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report | Pippias et al. [7] |
| 2    | Effects of exercise in the whole spectrum of CKD: a systematic review  | Barcellos et al. [8] |
| 3    | Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus | Kramer et al. [9] |
| 4    | The intestine and the kidneys: a bad marriage can be hazardous       | Vanholder et al. [10] |
| 5    | Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol? | Delanaye et al. [11] |
| 5    | Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma | Murakami et al. [12] |
| 5    | Strategies for preserving residual renal function in peritoneal dialysis patients | Nongrouch et al. [13] |
| 6    | Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling | Bhatnagar et al. [15] |
| 6    | The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials | Caluwe et al. [16] |
| 6    | Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis | Mann et al. [17] |
| 6    | Chronic kidney disease hotspots in developing countries in South Asia | Abraham et al. [18] |

Table 2. Overall most cited items published in 2017

| Rank | Title                                                                 | References |
|------|-----------------------------------------------------------------------|------------|
| 1    | The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary | Pippias et al. [19] |
| 2    | Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease | Pontillo and Mischak [20] |
| 2    | Age-dependent reference intervals for estimated and measured glomerular filtration rate | Pottel et al. [21] |
| 3    | Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome | Macion et al. [22] |
| 3    | Cognitive function and advanced kidney disease: longitudinal trends and impact on decision-making | Iyasere et al. [23] |
| 3    | Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the ‘Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease’ (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications | Pereira et al. [24] |
| 4    | Pregnancy outcomes in women on hemodialysis: a national survey       | Sachdeva et al. [25] |
| 4    | Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea | Brocklebank and Kavanagh [26] |
| 4    | Warfarin-related nephropathy induced by three different vitamin K antagonists: analysis of 13 biopsy-proven cases | Golbin et al. [27] |
| 5    | Lesinurad: what the nephrologist should know                          | Sanchez-Niño et al. [28] |
| 5    | Impact of poverty and race on pre-end-stage renal disease care among dialysis patients in the United States | Nee et al. [29] |
| 5    | The role of psychological factors in fatigue among end-stage kidney disease patients: a critical review | Picariello et al. [30] |

Note: As of 18 December 2018, according to Web of Science.
Table 3. Most cited items published in CkJ in 2018

| Rank | Title                                                                 | References |
|------|----------------------------------------------------------------------|------------|
| 1    | The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary | Kramer et al. [31] |
| 2    | Patterns of progression of chronic kidney disease at later stages     | Caravaca-Fontán et al. [32] |
| 2    | Pretreatment of enteral nutrition with sodium polystyrene sulfonate: effective, but beware the high prevalence of electrolyte derangements in clinical practice | Le Palma et al. [33] |
| 2    | Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graph3 study | Fouque et al. [34] |
| 2    | Women and kidney disease: reflections on World Kidney Day 2018: Kidney Health and Women’s Health: a case for optimizing outcomes for present and future generations | Piccoli et al. [35] |
| 2    | Cost of hemodialysis in a public sector tertiary hospital of India    | Kaur et al. [36] |
| 2    | Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi | Fankhauser et al. [37] |
| 2    | Do kidney transplantations save money? A study using a before–after design and multiple register-based data from Sweden | Jarl et al. [38] |
| 2    | Sevelamer reduces endothelial inflammatory response to advanced glycation end products | Gregório et al. [39] |
| 2    | Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study | Joseph et al. [40] |
| 2    | Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan | Müller et al. [41] |
| 2    | International Society of Nephrology’s 0by25 initiative (zero preventable deaths from acute kidney injury by 2025): focus on diagnosis of acute kidney injury in low-income countries | Raimann et al. [42] |
| 2    | Lung ultrasoundography in end-stage renal disease: moving from evidence to practice—a narrative review | Ross et al. [43] |
| 2    | Cardiovascular effects of metabolic syndrome after transplantation: convergence of obesity and transplant-related factors. | Sgambat et al. [44] |
| 2    | MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy? | Selvaskanandan et al. [45] |

Note: As of 18 December 2018, according to Web of Science.

6. Brück K, Stel VS, Fraser S et al. Translational research in nephrology: chronic kidney disease prevention and public health. Clin Kidney J 2015; 8: 647–655

7. Pippias M, Stel VS, Abad Diez JM et al. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. Clin Kidney J 2015; 8: 248–261

8. Barcellos FC, Santos IS, Umpierre D et al. Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. Clin Kidney J 2015; 8: 753–765

9. Kramer A, Pippias M, Stel VS et al. Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. Clin Kidney J 2016; 9: 457–469

10. Vanholder R, Glorieux G. The intestine and the kidneys: a bad marriage can be hazardous. Clin Kidney J 2015; 8: 168–179

11. Delanaye P, Ebert N, Melsom T et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol? Clin Kidney J 2016; 9: 682–699

12. Murakami N, Borges TJ, Yamashita M et al. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J 2016; 9: 411–417

13. Nongnuch A, Assanatham M, Panorchan K et al. Strategies for preserving residual renal function in peritoneal dialysis patients. Clin Kidney J 2015; 8: 202–211

14. Piccoli GB, Vigotti FN, Leone F et al. Low-protein diets in CKD: how can we achieve them? A narrative, pragmatic review. Clin Kidney J 2015; 8: 61–70

15. Bhattacharjee V, Richard EL, Wu W et al. Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling. Clin Kidney J 2016; 9: 444–453

16. Caluwé R, Pyfferen L, De Boeck K et al. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kidney J 2016; 9: 273–279

17. Mann MC, Hobbs AJ, Hemmelgarn BR et al. Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clin Kidney J 2015; 8: 41–48

18. Abraham G, Varughese S, Thandavan T et al. Chronic kidney disease hotspots in developing countries in South Asia. Clin Kidney J 2016; 9: 135–141

19. Pippias M, Kramer A, Noordzij M et al. The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary. Clin Kidney J 2017; 10: 154–169

20. Pontillo C, Mischak H. Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease. Clin Kidney J 2017; 10: 192–201

21. Pottel H, Delanaye P, Weekers L et al. Age–dependent reference intervals for estimated and measured glomerular filtration rate. Clin Kidney J 2017; 10: 545–551

22. Macia M, de Alvaro Moreno F, Dutt T et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J 2017; 10: 310–319

23. Iyase O, Okai D, Brown E. Cognitive function and advanced kidney disease: longitudinal trends and impact on decision-making. Clin Kidney J 2017; 10: 89–94

24. Pereira M, Rodrigues N, Godinho I et al. Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the ‘Risk, Injury, Failure, Loss of kidney function, End-
stage kidney disease’ (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications. Clin Kidney J 2017; 10: 332–340

25. Sachdeva M, Barra V, Thakkar J et al. Pregnancy outcomes in women on hemodialysis: a national survey. Clin Kidney J 2017; 10: 276–281

26. Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017; 10: 600–624

27. Golbin L, Vigneau C, Touchard G et al. Warfarin-related nephropathy induced by three different vitamin K antagonists: analysis of 13 biopsy-proven cases. Clin Kidney J 2017; 10: 381–388

28. Sanchez-Nino MD, Zheng-Lin B, Valino-Rivas L et al. Lesinurad: what the nephrologist should know. Clin Kidney J 2017; 10: 679–687

29. Nee R, Yuan CM, Hurst FP et al. Impact of poverty and race on pre-end-stage renal disease care among dialysis patients in the United States. Clin Kidney J 2017; 10: 55–61

30. Picariello F, Moss-Morris R, Macdougall IC et al. The role of psychological factors in fatigue among end-stage kidney disease patients: a critical review. Clin Kidney J 2017; 10: 79–88

31. Kramer A, Pippias M, Noordzij M et al. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. Clin Kidney J 2017; 11: 108–122

32. Carvaca-Fontán F, Azevedo L, Luna E et al. Patterns of progression of chronic kidney disease at later stages. Clin Kidney J 2018; 11: 246–253

33. Le Palma K, Pavlick ER, Copelovitch L. Pretreatment of end-stage renal disease: focusing on mineral and bone targets. Clin Kidney J 2018; 11: 166–171

34. Fouque D, Roth H, Darné B et al. Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study. Clin Kidney J 2018; 11: 73–79

35. Piccoli GB, Alrukhaimi M, Liu Z-H et al. Women and kidney disease: reflections on World Kidney Day 2018: Kidney Health and Women’s Health: a case for optimizing outcomes for present and future generations. Nephrol Dial Transplant 2018; 33: 189–193

36. Kaur G, Prinja S, Ramachandran R et al. Cost of hemodialysis in a public sector tertiary hospital of India. Clin Kidney J 2018; 11: 726–733

37. Fankhauser CD, Hermans T, Luger L et al. Extracorporeal shock wave lithotripsy versus flexible ureteroscopy in the treatment of untreated renal calculi. Clin Kidney J 2018; 11: 364–369

38. Jarl J, Desatnik P, Peetz Hansson U et al. Do kidney transplantsations save money? A study using a before-after design and multiple register-based data from Sweden. Clin Kidney J 2018; 11: 283–288

39. Gregorio PC, Favretto G, Sassaki GL et al. Sevelamer reduces endothelial inflammatory response to advanced glycation end products. Clin Kidney J 2018; 11: 89–98

40. Joseph A, Harel S, Venot M et al. Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study. Clin Kidney J 2018; 11: 20–25

41. Müller RU, Haas CS, Sayer JA. Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan. Clin Kidney J 2018; 11: 62–69

42. Raimann JG, Riella MC, Levin NW. International Society of Nephrology’s 0by25 initiative (zero preventable deaths from acute kidney injury by 2025): focus on diagnosis of acute kidney injury in low-income countries. Clin Kidney J 2018; 11: 12–19

43. Ross DW, Abbasi MM, Jhaeveri KD et al. Lung ultrasonography in end-stage renal disease: moving from evidence to practice—a narrative review. Clin Kidney J 2018; 11: 172–178

44. Sgambar K, Clauss S, Moudgil A. Cardiovascular effects of metabolic syndrome after transplantation: convergence of obesity and transplant-related factors. Clin Kidney J 2018; 11: 136–146

45. Selvaskanandan H, Pawluczyk I, Barratt J. MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy? Clin Kidney J 2018; 11: 29–37

46. Rodriguez-Ortiz ME, Pontillo C, Rodríguez M et al. Novel urinary biomarkers for improved prediction of progressive eGFR loss in early chronic kidney disease stages and in high risk individuals without chronic kidney disease. Sci Rep 2018; 8: 15940

47. Montinaro V, Gliberti M, Villani C et al. Citation classics: ranking of the top 100 most cited papers in nephrology. Clin Kidney J 2019; 12: 6–18

48. Pham PC, Khaing K, Sievers TM et al. 2017 update on pain management in patients with chronic kidney disease. Clin Kidney J 2017; 10: 688–697

49. Rak A, Raina R, Suh TT et al. Palliative care for patients with end-stage renal disease: approach to treatment that aims to improve quality of life and relieve suffering for patients (and families) with chronic illnesses. Clin Kidney J 2017; 10: 68–73

50. Christiadi D, Singer RF. Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation. Clin Kidney J 2018; 11: 528–529

51. Sparta G, Gaspert A, Neuhaus TJ et al. Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series. Clin Kidney J 2018; 11: 479–490

52. Musso CC, Castaneda A, Giordani M et al. Hypoatremia in kidney transplant patients: its pathophysiologic mechanisms. Clin Kidney J 2018; 11: 581–585

53. Wilkinson TJ, Watson EL, Gould DW et al. Pregnancy outcomes in the United States. Clin Kidney J 2017; 10: 332–340

54. Herringham KG, Preiss D, Haynes R et al. The role of psychological factors in fatigue among end-stage kidney disease patients: its pathophysiologic mechanism. Sci Rep 2018; 12: 113–121

55. Ruckel D, Keheila M, West B. Should donors who have used marijuana be considered candidates for living kidney donation? Clin Kidney J 2018; doi: 10.1093/ckj/sfy107

56. Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium–glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11: 749–761

57. Walsh PR, Tse Y, Ashton E et al. Clinical and diagnostic features of Bartter and Gitelman syndromes. Clin Kidney J 2018; 11: 302–309

58. Sprangers B, Nair V, Launay-Vacher V et al. Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J 2018; 11: 315–329